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Abstract
Background: The treatment of painful osteoporotic vertebral compression fractures has historically been limited to several
weeks of bed rest, anti-inflammatory and analgesic medications, calcitonin injections, or external bracing. Percutaneous
vertebroplasty (the injection of bone cement into the fractured vertebral body) is a relatively new procedure used to treat these
fractures. There is increasing interest to examine the efficacy and safety of percutaneous vertebroplasty and to study the
possibility of a placebo effect or whether the pain relief is from local anesthetics placed directly on the bone during the
vertebroplasty procedure.
Methods/Designs: Our goal is to test the hypothesis that patients with painful osteoporotic vertebral compression fractures
who undergo vertebroplasty have less disability and pain at 1 month than patients who undergo a control intervention. The
control intervention is placement of local anesthesia near the fracture, without placement of cement. One hundred sixty-six
patients with painful osteoporotic vertebral compression fractures will be recruited over 5 years from US and foreign sites
performing the vertebroplasty procedure. We will exclude patients with malignant tumor deposit (multiple myeloma), tumor
mass or tumor extension into the epidural space at the level of the fracture.
We will randomly assign participants to receive either vertebroplasty or the control intervention.
Subjects will complete a battery of validated, standardized measures of pain, functional disability, and health related quality of life
at baseline and at post-randomization time points (days 1, 2, 3, and 14, and months 1, 3, 6, and 12). Both subjects and research
interviewers performing the follow-up assessments will be blinded to the randomization assignment. Subjects will have a clinic
visit at months 1 and 12. Spine X-rays will be obtained at the end of the study (month 12) to determine subsequent fracture
rates. Our co-primary outcomes are the modified Roland score and pain numerical rating scale at 1 month.
Discussion:  Although extensively utilized throughout North America for palliation of pain, vertebroplasty still has not
undergone rigorous study. The study outlined above represents the first randomized, controlled study that can account for a
placebo effect in the setting of vertebroplasty.
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Background
Percutaneous vertebroplasty is the injection of polymeth-
ylmethacrylate (PMMA) bone cement into a painful verte-
bra, with the intention of providing stability and
subsequently relieving pain and restoring mobility. Dera-
mond and coworkers performed the first percutaneous
vertebroplasty in France in 1984, and reported success in
treating an aggressive vertebral hemangioma [1]. Soon
thereafter, vertebroplasty was also used for vertebral com-
pression fracture due to osteoporosis and tumor invasion
[1].
In the early 1990's, physicians in the United States (U.S.)
became interested in the use of percutaneous vertebro-
plasty principally for osteoporotic vertebral compression
fracture. Such fractures have an incidence of approxi-
mately 700,000/year in the U.S., affecting 25% of post-
menopausal women [2,3]. They may produce severe pain,
as well as an increased risk of death [4-6]. Although the
pain of an acute fracture is usually relieved within several
weeks by bed rest, anti-inflammatory and analgesic medi-
cations, calcitonin injections, or external bracing, it can
occasionally remain so severe that quality of life can be
maintained only with a narcotic analgesic medication [4-
6]. Moreover, prolonged immobilization caused by a frac-
ture can have harmful effects, such as acceleration of bone
resorption with increased risk for a new fracture, pneumo-
nia, deep venous thrombosis, and decubitus ulcers [7].
Methods/Design
Participants and Setting
INVEST (INvestigational Vertebroplasty Efficacy and
Safety Trial) is a multi-center, randomized, controlled trial
comparing percutaneous vertebroplasty to a control inter-
vention for patients with painful osteoporotic vertebral
compression fractures refractory to medical therapy. The
control intervention involves injection of a long-acting,
local anesthetic agent adjacent to but not within the verte-
bral body, and no injection of cement. Subjects will be
recruited from patients scheduled for vertebroplasty eval-
uations at participating US and foreign INVEST clinical
sites. Each INVEST site will be approved by their local
Institutional Review Board (IRB). Patients meeting the
inclusion criteria may enroll in the study following an
informed consent process.
Subjects must have a recent, painful vertebral compres-
sion fracture at levels T4 to L5 confirmed with a physical
examination and radiographic imaging. The fracture must
have occurred within the previous 12 months, they must
have tried medical therapy for pain and have a current
subjective pain rating of at least 3 on a 0 – 10 scale. Sub-
jects are required to have a confirmed diagnosis of oste-
oporosis or osteopenia. Patients are excluded if they have
malignant tumor deposit (multiple myeloma), tumor
mass or tumor extension into the epidural space at the
level of the fracture, malignancy, pedicle fracture, or cord
compression. Other eligibility criteria are: at least 50 years
old, no recent surgery (within 60 days), access to a tele-
phone, no local or systemic infection, no concomitant hip
fracture, no contraindications to conscious sedation,
speaks English well enough to answer all health ques-
tions, not pregnant, and no evidence of dementia (able to
give informed consent).
Baseline assessment
All subjects will complete baseline assessments prior to
the randomized treatment assignment. Subjects will pro-
vide the study with spine images (either plain film X-ray
or MRI) to document the fracture(s). The research coordi-
nator will complete a chart review to obtain pertinent
health variables, including height and weight, prior oste-
oporotic fractures and back procedures, osteoporosis his-
tory, current and historical osteoporosis therapy and oral
corticosteroid use, and current medication for back pain.
Subjects will complete a battery of standardized measures
of pain, physical disability and health related quality of
life, as well as comorbidities, back pain medications and
demographics. A brief physical examination will be per-
formed, including blood pressure and brief neurological
assessment (motor system, sensation, reflexes, and
straight leg raises).
Random Allocation
We will use a blocked randomization scheme with varia-
ble block sizes to ensure that the number of subjects in
each treatment group (percutaneous vertebroplasty vs.
control intervention) balances over time. We chose even
block sizes between 4 and 12 to minimize the possibility
that clinical staff will be able to guess the next treatment
allocation. Randomization will be stratified by enrolment
site. Random treatment assignments will be computer-
generated and delivered to sites in opaque, sealed enve-
lopes. The assignment will be revealed to the clinician in
the procedure room after the subject has been sedated and
has received local anesthesia.
Procedures
Both procedures will use full sterile preparation and be
placed prone on the angiographic table and receive con-
scious sedation by intravenous (IV) administration of fen-
tanyl and versed and/or other medications according to
the treating physician's usual practice. The subjects will
have their electrocardiogram (ECG), blood pressure, heart
rate and pulse oximetry continuously monitored through-
out the procedure in both treatment arms. Lidocaine will
be placed subcutaneously to numb the skin. Standard
fluoroscopy will be used for localization of the vertebral
body to be treated. The periosteum will be infiltrated with
Bupivacaine using fluoroscopic guidance. In both treat-BMC Musculoskeletal Disorders 2007, 8:126 http://www.biomedcentral.com/1471-2474/8/126
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ment arms a small incision will be made in the skin in the
vicinity of the pedicle to be treated. In the vertebroplasty
arm after placement of the access needle, the cement will
be mixed. The stylet will be removed leaving the cannula
in place for the injection of the PMMA. In the control arm
verbal clues will be given commenting on needle place-
ment and/or cement injection with manual palpation of
the area of the fracture to simulate needle placement. To
further simulate the vertebroplasty procedure a monomer
will be opened for the characteristic smell. Following the
procedure, all subjects will be observed in the full-supine
position for at least one hour. All subjects will be evalu-
ated prior to discharge for pain, new neurological dys-
function, or other potential complications of the
procedure. All subjects will be given the same instructions
regarding the bandages applied to the injection/incision
site and will be instructed to notify the physician with any
problems.
Crossover
If a subject has not improved by the one-month clinic
visit, a crossover to the other study intervention will be
offered. If the subject was randomized to vertebroplasty,
the crossover procedure will be the control intervention
(injection of a long-acting, local anesthetic agent). If the
subject was randomized to the control intervention, the
crossover procedure will be vertebroplasty. Subjects and
interviewers will remain blinded to treatment assignment
throughout the study, regardless of whether a crossover
occurs. In the case of a crossover, they will be blinded to
the order of the treatment assignments, even though they
will know that the subject has received both interventions.
Follow-up for crossover subjects will continue with the
schedule determined at the original randomization proce-
dure: crossover procedures have no impact on the follow-
up schedule. However, the one-month follow-up exami-
nation and interviews must be completed prior to the
crossover procedure. The subject may crossover to the
other procedure at any time during the study.
The study will fund the full cost of the control interven-
tion. Each site will be asked to delay the billing to the sub-
jects in an attempt to keep them blinded as to the
procedure they receive. The costs of the vertebroplasty will
be billed to the subject's insurance after the one-month
evaluation. Masking of the clinicians is not possible given
the nature of the interventions. The evaluators (the per-
sons conducting the follow-up interviews) will also
remain blinded to the treatment allocation. Every effort
will be made to maintain naiveness of the subjects and
evaluators during the course of the study.
All study participants will be assessed with in-person
interviews at baseline (prior to receiving the randomized
treatment) and one month, and one year. All other assess-
ments will be via telephone interviews.
Measures
Our primary outcomes are the modified Roland Scale [8]
(a measure of back pain-related physical disability) and a
0–10 numerical rating scale of pain intensity (0 = no pain,
10 = pain as bad as could be) [9]. A 2 or 3-point difference
on the Roland Scale is the smallest clinically important
difference found in studies of patients with other types of
back pain [8,10].
Subjects are asked about their use of medications (anti-
osteoporosis, analgesic, and steroid) to assess for poten-
tial confounding in the outcomes analyses. We will also
collect a self-report version of the Charlson comorbidity
index [11]. Secondary outcome measures include the
modified Deyo-Patrick Pain Frequency and Bothersome-
ness Scale [12], the SF-36 version 2 (a general health-
related quality of life measure) [13], the Strength of Func-
tion (SOF) and Activities of Daily Living (ADL), the EQ-
5D (a measure of health state preferences) [14], and the
Osteoporosis Assessment Questionnaire (OPAQ) body
image domain (an osteoporosis-specific functional status
instrument) [15].
A back pain resource use questionnaire is used to assess
the medical care costs associated with vertebroplasty. Sub-
jects are asked to provide information concerning outpa-
tient and office visits, including the medical specialty of
the provider; the number of visits; the tests, treatments, or
devices received at the visit; and the average length of time
for each visit. Hospitalizations and ambulatory surgery
are also recorded in the questionnaire. Finally, we will
assess the name, dose, and frequency of use of osteoporo-
sis medications, analgesics, and any other drugs poten-
tially used for back pain.
Adverse events and serious adverse events will be collected
at each time point (clinic visit and telephone call). Data
acquired at the visits and telephone calls is entered into
the electronic database. Any medical problems are
"caught" in the electronic system and an automatic e-mail
goes to the study principal investigator and the database
controller. This facilitates quick action on any serious
adverse event. The DSMB and NIAMS are notified of
adverse events using KAI, Research Inc. as the intermedi-
ary for notification.
Follow up radiographs will be completed for all subjects
at the 12 month clinical visit. The study will pay for these
x-rays. Adjacent fractures, if there are any, will be able to
be seen on these radiographs.BMC Musculoskeletal Disorders 2007, 8:126 http://www.biomedcentral.com/1471-2474/8/126
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We will screen each subject in the intervention group and
the cross-over subjects for implant-related, particulate-
induced granulomatous inflammation associated with
extensive localized bone resorption surrounding the
implant as well as vertebral fractures adjacent to treated
levels. The rates of these occurrences will be reported at
the completion of the study. Osteolytic responses in the
presence of an implant are not uncommon and may not
induce problematic levels of bone resorption. Extensive
bone resorption most likely would manifest itself in the
presence of symptomatic complications. Furthermore,
secondary or adjacent fractures can occur as a result of the
natural progression of the underlying disease and may not
be treatment related.
Each subject will answer questions about medical treat-
ment resource use at the telephone follow up calls and at
the clinic visits. This will be used for the cost analysis por-
tion of the study. Chart review will also be used to help
complete the cost analysis and drug usage of the subject
while participating in the study.
Analysis
Vertebroplasty will be considered successful if the follow-
ing criteria are met at 12 months post-randomization: a
50% improvement in pain related to treated fracture(s)
relative to baseline, a two-point improvement from base-
line on the Roland Scale, maintenance or improvement in
postoperative neurologic status as compared to preopera-
tive neurologic status (neurologic criteria for success
include lack of worsening of focal deficits or of radicular
pain, weakness, or numbness), absence of serious adverse
events that are device/treatment related (including sec-
ondary interventions addressing symptomatic events),
and absence of new fracture at treated level(s).
The control group success criteria differ slightly from that
of the treatment group because of the differences in treat-
ment and the presence/absence of a permanent implant.
The control group will be considered successful if the fol-
lowing criteria are met: a 50% improvement in pain
related to "treated" fracture(s) from baseline measure-
ment at one month, a two-point improvement from base-
line on the Roland Scale, maintenance or improvement in
postoperative neurologic status as compared to preopera-
tive neurologic status, absence of surgical intervention or
need for alternative to conservative medical therapy for
"treated" fracture, resolution of fracture at "treated" level
through conservative medical therapy.
We will assess the baseline equivalence of the vertebro-
plasty and control groups by comparing them in terms of
demographic characteristics, clinical findings, symptoms,
and functional status. We will similarly compare subjects
enrolled in the study sites. The distributions of the study
outcome variables will be examined, and may be trans-
formed, as necessary, prior to parametric tests or multivar-
iate analyses.
For primary analyses, an "intention-to-treat" strategy will
be employed, such that each subject is analyzed in the
group to which he or she is randomized, regardless of
actual compliance with the intended intervention. This
strategy requires minimal assumptions and maintains the
random allocation, although intervention effects may be
"diluted" if cross over between procedures is high. We will
stratify all analyses for site. Non-adherence and/or drop-
out complicate analysis of follow-up data. Consideration
of missing data is essential to characterize the potential for
selection bias through attrition. When appropriate, miss-
ing follow-up data for subjects who withdraw will be
imputed.
The primary outcomes of Roland and pain measure will
be assessed at the one-month time point. This allows ade-
quate time for any intervention benefit to manifest, and is
the final assessment prior to the opportunity to select fur-
ther treatment (crossover). The primary analysis will test
for the efficacy of vertebroplasty using a permutation test
based on the randomization distribution. Such analysis
allows formal inference relying solely on the random
assignment of subjects for validity (i.e., makes no addi-
tional statistical assumptions). Confidence intervals for
the magnitude of treatment effect will be obtained using
linear regression with a treatment indicator as the predic-
tor of interest and using dummy variables to stratify on
site. We will perform a similar analysis using the 0–10
numerical pain rating scale at one month. Secondary anal-
yses will describe the complete time profile for the Roland
and the pain ratings through one year using methods
appropriate for the analysis of repeated measures [16].
In addition to hypothesis tests based on the randomiza-
tion scheme, we will conduct secondary analyses that
adjust for important baseline characteristics, such as base-
line pain severity, and functional status. We will conduct
limited exploratory analyses to assess evidence for differ-
ential treatment response by subject subgroups by testing
treatment-covariate interactions for factors that are speci-
fied a priori in a detailed analysis plan to be created prior
to data analysis. We will also perform a subgroup analysis
examining whether enrolling early or late in the study had
an effect on outcome. This will help determine if a signif-
icant learning curve was present and, if so, the magnitude
of the effect.
Stratified 2-group methods will compare the intervention
groups on the secondary outcomes at 1-month, and lon-
gitudinal analysis using linear mixed models will be used
to characterize and compare the time course for the inter-BMC Musculoskeletal Disorders 2007, 8:126 http://www.biomedcentral.com/1471-2474/8/126
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vention groups. In addition, we will compare the two
groups controlling for baseline covariates including study
site, demographics, clinical characteristics, and co-mor-
bidities such as including medical and psychological fac-
tors.
We will test the hypothesis that vertebroplasty is a cost-
effective procedure for reducing pain and dysfunction due
to osteoporotic vertebral fractures. We will calculate the
costs to health care providers of care in the first year fol-
lowing randomization. We believe that the 12-month
time-frame will allow adequate measurement of the
important differences in cost and outcome between treat-
ment arms. However, if significant differences persist at
one year, we will construct a decision model to extrapo-
late the results. As an exploratory analysis, we will build a
worst-case scenario model that assumes that any benefits
of vertebroplasty fall off rapidly over time such that after
5 years benefits are equal between groups. Survival will be
based on published studies of mortality amongst an oste-
oporotic population [17,18]. All costs and benefits
beyond one year will be discounted at 3%, according to
U.S. guidelines [18].
We will combine utilization information recorded in the
resource use questionnaire with unit cost information
available for drugs [19], office visits [20], office-based
tests and procedures, and hospitalizations [21]. The total
cost will exclude the cost of the control procedure, both
for subjects initially randomized to this procedure and
those who later cross over to the control procedure. The
costs of the radiographs necessitated by the study protocol
at 12 months post-randomization will also be excluded.
Costs to healthcare payers will be combined with the out-
of-pocket cost to patients of obtaining health care to cal-
culate the total incremental cost to society of vertebro-
plasty. All costs will be adjusted to a common year using
the medical care component of the consumer price index
[18].
The primary economic outcome measure is the EQ-5D
preference score [22]. The EQ-5D assesses three levels of
severity (no problems, moderate problems, and extreme
problems) across each of five dimensions of health
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression). Responses to the EQ-5D can be con-
verted into a weighted health state index using predeter-
mined values derived from general population surveys
[22]. This index is anchored at zero (very severe health sta-
tus equivalent to death) and one (best imaginable health
status). By combining this quality of life index with infor-
mation on patient survival, a quality adjusted life year
(QALY) can be calculated.
We will calculate the incremental net benefit (INB) statis-
tic of vertebroplasty, defined as:
INB = λ(Effectvertebroplasy - Effectcontrol) - (Costvertebroplasty - 
Costcontrol),
where λ is the amount that society is willing to pay for an
average improvement of one quality adjusted life year.
Rather than use one arbitrary cut-off (e.g., $100,000 per
QALY) to define cost-effectiveness, we will present the
results as a cost-effectiveness acceptability curve (CEAC).
The CEAC uses non-parametric bootstrap methods [16] to
determine, for any given willingness-to-pay cut-off, the
probability that vertebroplasty is cost-effective. CEAC
curves enable decision-makers with different budget con-
straints to judge the cost-effectiveness of interventions in
their setting.
In the primary analysis, we will exclude subjects with
missing cost or effectiveness data. However, as data may
not be missing at random, we will conduct a secondary
analysis using multiple imputation methods to estimate
missing data [23]. We will use univariate and multivariate
sensitivity analysis to estimate which non-stochastic
parameters (e.g. unit costs, discount rate) have the greatest
influence on our findings.
The serious adverse event (SAE) complication rates occur-
ring within one month of surgery for the device-treated
and control subjects will be evaluated descriptively in
aggregate and separately. The SAE rate for each group will
be estimated and the corresponding 95% exact binomial
confidence intervals will be computed. If the number of
events is sufficiently large to allow more sophisticated
analysis, the rates between the vertebroplasty and control
subjects will be compared by logistic regression with cov-
ariate adjustment. The data will be presented by total
numbers of events and by total numbers of subjects with
at least one event. The complication rates including sub-
sequent fractures will be descriptively analyzed through
two years post-treatment. The rates and the corresponding
95% exact confidence intervals will be computed.
Based on 12-month plain radiographs, as compared to
baseline radiographs, we will compare the proportion of
subjects in the two study arms suffering at least one new-
onset fracture using the binomial test. We will use the Stu-
dent t-test to compare the two groups in terms of the
mean number of new fractures and the mean number of
vertebral levels between the treated levels and new frac-
ture levels.
Non-serious adverse events will be tabulated individually
and overall through one year post treatment. The rates will
be estimated for the device-treated and control subjectsBMC Musculoskeletal Disorders 2007, 8:126 http://www.biomedcentral.com/1471-2474/8/126
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separately and the exact binomial 95% confidence limits
will be calculated.
Safety Monitoring
If at any time after the procedure (vertebroplasty or con-
trol) is performed there are any changes in physical
health, the event(s) will be reported to the appropriate
authorities (DSMB, NIH, and all site PIs and IRBs) as soon
as it is known and will be followed until resolution.
An external six-member Data Safety Monitoring Board
(DSMB) is monitoring the study in accordance with
NIAMS guidelines. The DSMB determined appropriate
stopping criteria and will review the data after 73 and 90
subjects have one-month Roland and pain outcomes for
evidence of treatment efficacy or unusual rates of adverse
outcomes. KIA Research, Inc. manages the safety monitor-
ing for NIAMS, and serious adverse events will be reported
directly to NIAMS and KIA Research, Inc., who will dis-
tribute this information to the DSMB chair and safety
officer, as they occur. Subsequent vertebral fractures (adja-
cent and non-adjacent) will be a reportable event, not an
adverse event. The principal investigator will notify each
site IRB of any death regardless of where the death
occurred.
Sample Size
In unpublished pilot data on 88 patients, we found an 8.6
point average reduction on the Roland (standard devia-
tion of 6.7) at 4 weeks following the vertebroplasty proce-
dure. We originally planned to enroll 249 subjects but had
to adjust our expectations to 166 subjects due to difficulty
with enrolment. With at least 90% follow-up at one
month, we expect to have 75 subjects in each arm (150
total) assessed. This sample size yields 95% power to
detect a 4-point effect size, and maintains good power for
a 3-point effect size (78% power).
We will use a 0–10 numerical pain rating scale to test the
hypothesis that short and long-term pain relief is greater
in the percutaneous vertebroplasty group than in the con-
trol group. In a pilot study, we found a mean reduction of
7.1 (2.7 SD) points on this pain rating scale in a group of
patients who received vertebroplasty [24]. A sample size
of 150 has greater than 95% power to detect an effect size
of 1.75 and a greater than 80% power to detect a 1.25-
point effect size.
Data Management
Data acquisition, handling, and storage are under the
direction of the senior programmer of the Data Coordi-
nating Center at the University of Washington. An HTML
form-based web application is in use for conducting sub-
ject assessments as an efficient method for managing data
for this multi-center, national trial. Data will be housed in
a secure, centralized database at the University of Wash-
ington. The system will automatically perform edit and
logic checks to validate the data for quality and complete-
ness as they are being entered. A quality control audit will
be performed on a monthly basis and the results printed
in an interim report. Staff at the data-coordinating center
will monitor the compliance of each study hospital with
the study procedures and data quality.
We will document the number and proportion of subjects
eligible for and compliant with each follow-up. Careful
efforts will be made to minimize missing data, though
some will inevitably occur. Subjects who withdraw from
the study will be tabulated with the reasons for the with-
drawal. Subjects who die during the study (unrelated to
study or procedure) will be tabulated also. If the propor-
tion of subjects withdrawn is larger than the expected 15%
at one month and additional 10% at one year from either
arm, an analysis of the demographic and prognostic char-
acteristics will be made between subjects who withdraw
and those who remain in the study. For continuous varia-
bles, parametric or non-parametric analysis of variance
will be used. For categorical variables, Chi-square or
Fisher's exact test will be applied.
When individual items are missing from a scale, we will
calculate the percent of missing items. If the missing items
are less than 10%, we will impute values using the mean
of the remaining items. If more than 10%, the scale score
will be missing, and unavailable for analysis at that time
point.
Discussion
Although extensively utilized throughout North America
for palliation of pain, vertebroplasty still has not under-
gone rigorous study. The study outlined above represents
the first randomized, controlled study that can account for
a placebo effect in the setting of vertebroplasty.
Waning enrolment caused the addition of foreign sites to
the study to have the number of subjects needed for an
acceptable sample. Approval was obtained from the State
Department and the NIH and some foreign sites were ini-
tiated into the study and enrolment increased. We now
anticipate enrolling a total of 100 subjects. Assuming a
90% follow up rate at one month, we maintain good
power (80%) to detect group differences in Roland of 4.0
or more and 87% power for differences in pain of at least
1.75.
Results from this study should provide compelling evi-
dence as to whether or not internal stabilization of non-
healing, painful, osteoporotic vertebral compression frac-
tures offers clinical benefit.Publish with BioMed Central    and   every 
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Conclusion
Achieving the sample size of enrolled participants will be
difficult especially as the eligibility criteria are so limiting
and most potential vertebroplasty patients come from
quite a distance and are not willing to return at one month
and one year.
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